Author: Kevin Grogan

France’s Ipsen has bought an option to acquire the UK’s Canbex Therapeutics, which is working on a treatment for spasticity in people with multiple sclerosis.

Merck & Co has inked a deal with the Medicines Patent Pool for its HIV drug Isentress (raltegravir) to be used for children.

Bristol-Myers Squibb is to acquire privately-held Flexus Biosciences in a deal worth up to $1.25 billion.

Shares of Celldex Therapeutics jumped nearly 17% on the news that the US Food and Drug Administration has granted breakthrough therapy designation to its brain cancer immunotherapy Rintega.

Japan’s Sosei has acquired Heptares Therapeutics of the UK in a deal that could be worth up to $400 million.